Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Paradigm Biopharmaceuticals ( (AU:PAR) ) just unveiled an announcement.
Paradigm Biopharmaceuticals reported continued operational progress in the December 2025 quarter, advancing its global Phase 3 PARA_OA_012 trial of injectable pentosan polysulfate sodium for knee osteoarthritis pain, with most sites in Australia and the United States now active and additional locations in Hong Kong and Moldova set to commence screening to bolster recruitment and geographic diversity. The company highlighted that Hong Kong participation aligns with a new regulatory pathway that could support future registration flexibility, while the publication of Phase 2 biomarker data in a leading peer-reviewed journal provides important external validation of iPPS’s biological effects and underpins regulatory and commercial engagement, alongside a solid cash position and further translational work in canine osteoarthritis designed to strengthen the scientific case for its lead asset.
The most recent analyst rating on (AU:PAR) stock is a Hold with a A$0.32 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on developing injectable pentosan polysulfate sodium (iPPS) as a treatment for pain associated with osteoarthritis, particularly knee osteoarthritis, targeting a global market with high unmet need in musculoskeletal disorders.
Average Trading Volume: 885,894
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$138.7M
For detailed information about PAR stock, go to TipRanks’ Stock Analysis page.